Expression and clinical significance of CD147 in renal cell carcinoma: a meta-analysis

Hui Li1,*, Dongwen Wu2,*, Shupeng Shi2, Yadong Xu2, Ling Wei2, Jing Liu2 and Yanting Liu2

1 Reproductive Department, Xiangya Hospital, Central South University, Changsha, China
2 Xiangya School of Medicine, Central South University, Changsha, China
* These authors have contributed equally to this work

Correspondence to: Hui Li, email: HUILI257@hotmail.com

Keywords: renal cell carcinoma, CD147, case control study, meta-analysis

Received: September 26, 2016 Accepted: February 21, 2017 Published: April 10, 2017

Copyright: Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Objective: To assess clinical significance of CD147 in renal cell carcinoma.

Methods: Collect case-control studies which focus on CD147’s expression in renal cell carcinoma. Trails were retrieved from CBM, CNKI, Wan-fang database, PubMed, Cochrane Library and Embase. According to the inclusion and exclusion criteria, data extraction and quality assessment were done by two researchers independently, and outcomes were pooled with Revman5.3 and STATA14.0.

Results: A total of 11 studies were confirmed, among which renal cell carcinoma 887 cases, non-cancer 505 cases. As for the positive rate of CD147, there are statistical differences among survival, renal cell carcinoma tissue vs. non-cancer tissues [OR=8.19, P=0.0002], with vs. without lymph node metastases [OR=6.52, P=0.001], clinical stage III~IV vs. II~I [OR=4.07, P<0.00001], histopathological stage III~IV vs. II [OR=3.01, P=0.002], histopathological stage III~IV vs. I [OR=7.50, P<0.00001], tumor size [OR=5.01, P=0.0007]. No significant difference was tested among different age, gender, histological types and Position of cancer.

Conclusion: As shown in our results, CD147 may participate the whole course of carcinogenesis of renal cell carcinoma, which might be valuable for the diagnosis, treatment and prognosis.

INTRODUCTION

Renal cell carcinoma (RCC) is the most common malignancy of kidneys found in adults [1]. It is the seventh most common cancer in man and the tenth in women, which account for 2%–3% of all adult malignancies [2]. The incidence of RCC is increasing rapidly on average 1.1% over the last ten years [3]. In the United States, there are more than 62,000 new cases of RCC and at least 14,000 deaths expected in 2016 [2]. Tumor metastasis is the main cause of mortality and treatment failure in RCC patients [4]. Unfortunately, because of the lack of obvious symptoms during the early stage, up to 20–30% RCC patients present with metastatic disease [5]. Therefore, it is of great significance to search for sensitive and specific markers that can provide valuable information for the early diagnosis and prognosis of RCC. A number of biomarkers such as survivin, MCT1, MCT4, Cullin 1 and CD147 have been found to be involved in its development and progression according to some reports [6-8]. Among these markers, extracellular matrix metalloproteinase inducer (EMMPRIN, also known as CD147 or basigin) is highly expressed in a variety of tumors, facilitating tumor invasion and metastasis [9]. Studies show that CD147 is up-regulated in a lot of malignancies, including breast, lung, oral, esophageal, laryngeal and renal cancers [6, 10-14]. So there is great possible that CD147 can serve as a prognosis biomarker for RCC. But the expression profiles of CD147 in RCC are controversial. For example, some studies show a significant difference among the subtypes of RCC while some studies argue about this [15-18]. The same conflict is also seen in the studies of metastasis status and TNM stage [16, 18-20].
These controversies could be a result of differences in sample sizes and other factors, such as the criterial of the positive expression of CD147, and unfortunately evidence-based confirmation by large-scale clinical trials is still lacking. Therefore, we conducted this meta-analysis to quantitatively inspect the relationship between CD147 and clinicopathological features and survival of renal cancer patients.

RESULTS

Literature search

A total of 259 studies were identified, and 176 studies were excluded because of duplication. After reading the titles and abstracts, 44 studies were excluded. 39 possible full text studies were carefully reviewed (animal studies [n = 15]; review and meta-analysis [n = 11]; no control group [n = 2]). Finally, 11 trials were included for quantitative analysis [15–20, 22–26] (Figure 1). Their characteristics are summarized in Table 1 and NOS score are showed in S2 Appendix.

CD147 expression and survival

We investigated the relationship between CD147 expression 1-,3-,5-,10- and 15-survival. Fixed-effects model was used for all them without heterogeneity. As expected, the positive expression of CD147 indicated worse long-term survival with significant difference (Table 2, and Supplementary Figure 1). In addition, five data sets [16, 18, 19, 23, 24] with 5-year overall survival HR (hazard ratio) are available, and all the studies reported the univariate result. We combined the data with fixed model effect (I2=0, P=0.728), and found that CD147 positive expression bring a worse 5-year survival comparing with negative patients (HR=1.61, 95%CI= 1.04-2.49) (Figure 2).

CD147 in renal cancer and non-cancer tissues

Eight studies [15–17, 20, 22, 24–26] with 1392 patients was enrolled in the positive expression of CD147 in renal cancer tissues and non-cancer tissue, which include normal tissue and para-carcinoma tissue, with 7 studies focus on protein level and 2 studies on mRNA. With significant heterogeneity (P= 0.02, I2= 66%), random-effects model showed the CD147 positive rate in renal cancer tissues was higher (83.99% vs. 75.84%) (OR= 8.19, 95%CI= (2.74, 24.52), P= 0.0002) (Figure 3). Subgroup analysis of different estimated level showed the same result (protein level OR= 8.59, 95%CI= (2.20, 33.52), P= 0.002; mRNA level OR= 7.93, 95%CI= (2.44, 25.77), P= 0.0006).

---

**Figure 1: PRISMA 2009 flow diagram.** A total of 259 studies were identified, and 176 studies were excluded because of duplication. After reading the titles and abstracts, 44 studies were excluded. 39 possible full text studies were carefully reviewed (animal studies [n = 15]; review and meta-analysis [n = 11]; no control group [n = 2]). Finally, 11 trials were included for quantitative analysis.
CD147 expression and lymph metastasis

Four studies [19, 20, 24, 25] with 417 patients reported metastasis, including 3 studies focus on the CD147 protein level and 1 studies on mRNA. Without significant heterogeneity (P= 0.98, I² = 0%), fixed-effects model showed CD147 positive expression in lymph metastasis patient was more frequently than non-metastasis patient (96.77% vs. 76.34%) (OR= 6.52, 95%CI= (2.08, 20.38), P= 0.001) (Figure 4A). Protein level subgroup analysis showed the same conclusion (OR= 5.96, 95%CI= (1.72, 20.62), P= 0.005). While mRNA level subgroup showed no significant difference with only one study.

CD147 expression and clinical stage

Totally 8 [15–17, 19, 20, 24–26] studies reported TNM Staging System (UICC, 2009), some studies reported the difference of TNM1, TNM2 and TNM3-4 separately while others reported TNM1-2 and TNM3-4. No data compare the difference of TNM3 with TNM4. Therefore, firstly, we compared the difference between TNM1 and TNM2 with 6. Without heterogeneity, fixed-effects model showed there is no difference two groups (OR= 1.42, 95%CI= (0.85, 2.37), P=0.19) (Figure 4B). Then we combined TNM I and TNM II together as a group to compare with TNM III~IV with 9 date sets was available. Without heterogeneity, fixed-effects model suggested that the positive expression of CD147 had a great correlation with higher TMN stage no matter on protein (OR= 3.52, 95%CI= (2.06, 6.01), P< 0.00001) or mRNA level (OR= 9.01, 95%CI= (2.44, 33.34), P= 0.0010) (Figure 4C).

CD147 expression and histopathological stage

The comparision of original individual studies among different histopathological stage (The Robson Staging System of Renal Cell Carcinoma) are similar to clinical stage, so we first combined the comparing of histopathological stage I vs II, and the result had a significant difference (OR= 3.15, 95%CI= (1.20, 8.30), P= 0.0002) (Figure 4D). Therefore, we compared stage I and II with stage III~IV separately using fixed-effects model. Both of them showed that positive of CD147 were related to high histopathological stage (III~IV vs. I: OR= 7.50, 95%CI= (4.53, 12.40), P< 0.00001; III~IV vs. II: Table 1: Characteristics of eligible studies

| First Author | Year | Origin | Median Age | Cases | Counting method | Definition of CD147 positive | Survival results | HR | follow-up time (month) | NOS score |
|--------------|------|--------|------------|-------|-----------------|-----------------------------|-----------------|----|------------------------|-----------|
| Jin, J S[23] | 2006 | Taiwan | N          | 79    | POSITIVE CELL PERCENTAGE*STAINING INTENSITY | >0% or weak intensity | OS              | Univariate | 70                      | 7         |
| Kim, Y[19]   | 2015 | Korea  | 58         | 180   | POSITIVE CELL PERCENTAGE*STAINING INTENSITY | >0% or weak intensity | OS              | Univariate | 173                     | 7         |
| Liang, Y X[22] | 2009 | China  | 63.5       | 53    | STAINING INTENSITY | Brown | OS              | Univariate | 12                      | 8         |
| Rabien, A[16] | 2013 | Germany | 60         | 394   | POSITIVE CELL PERCENTAGE*STAINING INTENSITY | >0% or weak intensity | OS              | Univariate | 194                     | 8         |
| Tsai, W C[18] | 2007 | Taiwan | N          | 93    | POSITIVE CELL PERCENTAGE*STAINING INTENSITY | >5% or weak intensity | OS              | Univariate | 70                      | 7         |
| Liu Z[24]     | 2007 | China  | 53         | 80    | POSITIVE CELL PERCENTAGE*STAINING INTENSITY | >0% or weak intensity | OS              | Univariate | 87                      | 7         |
| Ke M[17]      | 2013 | China  | 51.2       | 82    | STAINING INTENSITY | Brown | N               | N             | N                       | N         |
| Wang SC[20]   | 2011 | China  | 56.3       | 107   | STAINING INTENSITY | Brown | N               | N             | N                       | N         |
| Luo HR[15]    | 2016 | China  | 56.3       | 85    | STAINING INTENSITY | Brown | N               | N             | N                       | N         |
| Chen YB[26]   | 2010 | China  | 51.8       | 43    | STAINING INTENSITY | Brown | N               | N             | N                       | N         |
| Ma Y[25]      | 2009 | China  | 58         | 50    | PCR              | N     | N               | N             | N                       | N         |

positive cell percentage: 0 point for positive cell percentage≤ 25%; 1 point for 26%-50%; 2 points for 51%-75%; 3 points for>75%;
Staining intensity: 0 point for basically no coloration, 1 point for light yellow, 2 points for pale brown, and 3 points for dark brown; N: not mention; OS: overall survival;
Table 2: CD147 expression and survival

| Survival years | Heterogeneity | OR  | 95%CI | P      |
|----------------|--------------|-----|-------|--------|
|                | P            | F   |       |        |
| 1-year         | 0.24         | 25% | 0.36  | (0.20, 0.66) | < 0.0001 |
| 3-year         | 0.70         | 0%  | 0.39  | (0.25, 0.60) | < 0.00001 |
| 5-year         | 0.56         | 0%  | 0.41  | (0.28, 0.61) | < 0.00001 |
| 10-year        | 0.70         | 0%  | 0.39  | (0.26, 0.57) | < 0.00001 |
| 15-year        | 0.27         | 17% | 0.40  | (0.28, 0.59) | < 0.00001 |

Figure 2: Forest Plot showing the results of meta-analyses of CD147 expression and survival. (A) 1-year survival rate for CD147 positive expression was worse. OR= 0.36, 95%CI= (0.20, 0.66), P= 0.0008. (B) 3-year survival rate for CD147 positive expression was worse. OR= 0.39, 95%CI= (0.25, 0.60), P< 0.0001. (C) 5-year survival rate for CD147 positive expression was worse. OR= 0.41, 95%CI= (0.28, 0.61), P< 0.00001. (D) 10-year survival rate for CD147 positive expression was worse. OR= 0.40, 95%CI= (0.28, 0.59), P< 0.00001. (E) 15-year survival rate for CD147 positive expression was worse. OR= 0.40, 95%CI= (0.28, 0.59), P< 0.00001. (F) 5-year HR for CD147 positive expression was worse. HR= 1.61, 95%CI= (1.04, 2.49), P=0.015.
OR= 3.01, 95%CI= (1.48, 6.15), P= 0.002) (Figure 4E, Figure 4F).

**CD 147 expression with other clinicopathologic characteristics**

Except for tumor size (Supplementary Figure 2A: big vs. small: OR= 5.01, 95%CI= 1.97, 12.73, P= 0.0007), there is no statistic difference between positive expression and negative, such as age (Supplementary Figure 2B: old vs. young: OR= 1.24, 95%CI= (0.83, 1.85), P= 0.30), gender (Supplementary Figure 2C: male vs. female: OR= 0.90, 95%CI= (0.59, 1.36), P= 0.62), histological type (Supplementary Figure 2D: clear cell carcinoma vs. others: OR= 1.47, 95%CI= (0.86, 2.50), P= 0.16) and the position of tumor (Supplementary Figure 2E: higher pole vs. lower pole: OR= 1.47, 95%CI= (0.86, 2.50), P= 0.16) without heterogeneity.

**Sensitivity analysis and publication bias**

We exclude study one by one to evaluate the influences of individual studies on the final effect and all the results, except 5-year survival HR, are consist with the result of including all studies (Supplementary Figure 3 sensitivity analysis), which mean our results are stable and reliable. Egger test was applied to test publication bias, publication bias did not test for almost of the result, except 4 outcomes (clinical stage II vs. I, histopathologic stage III–IV vs. II, 10-year survival and tumor size (bigger vs. small)) had a P value lower than 0.05 (Supplementary Figure 1 publication bias). By trim and fill method, both the results of fixed and random effects model are just the same with original result (S3 Appendix) (Table 3).

**Bioinformatics analysis**

First, by using the GOpubmed, we explored that the discovery of CD147 was in 1990 and since then it is becoming more and more popular especially in recent years (Figure 5A). In addition, most of research related to CD147 was investigated in China (142 publications) and the USA (141 publications), followed by Japan (65 publications) (Figure 5B and 5C). Besides, we can see the author networks in Figure 5D. And the top 20 author was show in Figure 5E. Second, string version10 analysis result showed the interaction between CD147 and other protiens (Figure 6A–6D). Figure 6A, active interaction sources restricted only on experiment data and B-D without sources restriction. A-B with high confidence (0.700) while C-D with medium confidence (0.400). A-C with max number of interactors 50 for first shell and 5 for the second shell, while D with 50 for the first shell and the second shell. For more details of information can be seen in supplementary file. Third, IPA (Ingenuity PathwayAnalysis) result showed in Figure 7A–7D without species and sources restriction of the data setting. Figure 7A showed total interaction network of CD147 with other molecules (252 molecules) including protein and micro-RNA and their cellular location (extracellular space, plasma membrane, cytoplasm, nuleus.

![Figure 3: Forest Plot showing the results of meta-analyses of CD147 in renal cancer and non-cancer tissues. The CD147 positive rate in renal cancer tissues was higher (OR= 8.19, 95%CI= (2.74, 24.52), P= 0.0002). Protein level (OR= 8.59, 95%CI= (2.20, 33.52), P= 0.002) and mRNA level (OR= 7.93, 95%CI= (2.44, 25.77), P= 0.0006) came to the same conclusion.](image-url)
and other organelle) and red labeled mean the molecular is related to cancer. We can know almost of all the interaction molecular is related to cancer (233/252, 92.5%). Figure 7B, red labeled in the molecular related to tumorgenesis (221/252, 87.7%). Figure 7C labeled with Blue linked line molecular is related to molecular mechanisms of cancer. And Figure 7D show the molecular mechanism signaling pathway and the red labeled molecular is the same molecular linked with blue line in Figure 7C. Besides, we explored the interaction between CD147 and MAPK, AKT, ERK, VEGF which is the most core molecular in their signaling pathway (Figure 8A–8D).

Figure 4: Forest Plot showing the results of meta-analyses of CD 147 Expression lymph metastasis, clinical stage and histopathological stage. (A) CD 147 positive expression in lymph metastasis patient was more frequently than non-metastasis patient (OR= 6.52, 95%CI= (2.08, 20.38), P= 0.001). (B) CD 147 positive expression in TNM1 and TNM2 was no statistical difference (OR= 1.42, 95%CI= (0.85, 2.37), P=0.19). (C) CD 147 positive expression had a great correlation with higher TNM stage (OR= 4.07, 95%CI= (2.48, 6.67), P< 0.00001). (D) CD 147 positive expression in histopathological stage I vs II had significant difference (OR= 3.15, 95%CI= (1.20, 8.30), P= 0.0002). (E) CD 147 positive expression had a great correlation with higher histopathological stage when compared III–IV with I (OR= 7.50, 95%CI= (4.53, 12.40), P< 0.00001). (F) CD 147 positive expression had a great correlation with higher histopathological stage when compared III–IV with II (OR= 3.01, 95%CI= (1.48, 6.15), P= 0.002).
DISCUSSION

CD 147, also known as extracellular matrix metalloproteinase inducer (EMMPRIN), is a heavily glycosylated immunoglobulin [27]. Also there are numerous clinical study in renal carcinoma to test whether CD 147 can be a biomarker. However, the clinical relevance of CD147 remains controversial. In the current meta-analysis, we pooled the data from 13 studies together [15–20, 22–26, 35, 36], and demonstrated a remarkable association between CD147 expression of patients with renal cancer.

As shown, CD 147 is a good predictor for the survival of renal cancer patients. No matter for 1-, 3-year short term or 5-, 10-, 15-year long term survival, patients with positive expression of CD 147 did much worse than negative expression patient.

When we come to investigate the different CD 147 expression among cancer tissue and non-cancer tissue, results consist with the conclusion in other cancer [30, 32–34], which show cancer tissue is positive for CD 147 with significant statistic difference on both mRNA (OR= 7.93, 95%CI=(2.44, 25.77), P= 0.0006) and protein level (OR= 8.59, 95%CI= (2.20, 33.52), P= 0.002). So this is a good proof for CD 147 to be a potential biomarker to renal cancer.

We compared the expression of CD 147 among different lymph metastasis, clinical stage, histopathological stage, age, gender, histological type and the position of tumor to test the relationship between CD 147 and clinicopathologic characteristics. In a word, CD 147 is strongly associated with poor clinical features. Patients with lymph metastasis (OR= 6.52, P= 0.001), advanced TNM stage (OR= 4.07, P< 0.00001) and poorly differentiated histopathologic stage (III~IV vs. I: OR= 7.50, P< 0.00001; III~IV vs. II: OR= 3.01, P= 0.002) stage always have a higher expression of CD 147. However, the level of CD 147 is not bound up with age (old vs. young: P= 0.30), gender (male vs. femal P= 0.62) and position of tumor (higher pole vs. lower poleP= 0.16). Interestingly, although renal cell carcinomas are very different among histological subtypes, we found there was no differences by comparing the CD147 positive expression between clear cell RCC and other types (P= 0.16).

Table 3: Sensitivity Analysis and Publication bias

|                         | OR Fluctuation | 95%CI Fluctuation | Publication bias (P value) |
|-------------------------|----------------|-------------------|---------------------------|
| Cancer and non-Cancer   | 6.41–10.88     | 2.16–34.04        | 0.142                     |
| Lympho metastasis       | 5.96–7.86      | 1.49–41.53        | N                         |
| Clinical stage:         |                |                   |                           |
| III–IV vs. I–II         | 4.75–6.77      | 2.48–11.64        | 0.805                     |
| Histopathologic stage:  |                |                   |                           |
| III–IV vs. I            | 7.12–8.31      | 3.55–14.43        | 0.689                     |
| III–IV vs. II           | 2.35–3.58      | 1.08–9.43         | 0.008*                    |
| Survival rate:          |                |                   |                           |
| 1-year                  | 0.24–0.44      | 0.11–0.80         | 0.699                     |
| 3-year                  | 0.34–0.46      | 0.19–0.73         | 0.932                     |
| 5-year                  | 0.38–0.47      | 0.23–0.70         | 0.367                     |
| 10-year                 | 0.32–0.41      | 0.17–0.63         | 0.015*                    |
| 15-year                 | 0.28–0.46      | 0.13–0.72         | N                         |
| 5 year overall survival |                |                   |                           |
| hazard ratio:           | 1.52–1.74      | 0.93–3.11         | 0.715                     |

Other clinicopathologic characteristics

|                         |                |                   |                           |
| tumor size              | 3.02–5.96      | 1.69–18.49        | 0.016*                    |
| Age                     | 1.17–1.31      | 0.73–2.03         | 0.890                     |
| Gender                  | 0.81–1.03      | 0.49–1.60         | 0.191                     |
| Histological type       | 1.18–1.63      | 0.64–3.08         | 0.961                     |
| Position of cancer      | 0.70–0.98      | 0.25–3.56         | N                         |

Note: P <0.05, exist Publication Bias; N for insufficient observations.
Figure 5: GO pubmed information. (A) The discovery of CD147 was in 1990 and since then it is becoming more and more. (B and C) The most of research related to CD147 was investigated in China (142 publications) and the USA (141 publications), followed by Japan (65 publications). (D) Author networks. (E) The top 20 author.
Figure 6: String interaction. (A) Active interaction sources restricted only on experiment data with high confidence (0.700), max number of interactors 50 for first shell and 5 for the second shell. (B) High confidence (0.700) without sources restriction, max number of interactors 50 for first shell and 5 for the second shell. (C) Medium confidence (0.400) without sources restriction, max number of interactors 50 for first shell and 5 for the second shell. (D) Medium confidence (0.400) without sources restriction 50 for the first shell and the second shell.
Figure 7: IPA interactions. (A) Total interaction network of CD147 with other moleculars (252 moleculars) including protein and micro-RNA and their cellular location (extracellular space, plasma membrane, cytoplasm, nuleus, and other organelle) and red labeled mean the molecular is related to caner. (B) Red labeled in the molecular related to tumorgensis (221/252, 87.7%). (C) Labeled with Blue linked line molecular is related to molecular mechanisms of cancer. (D) The molecular mechanism signaling pathway and the red labeled molecular is the same molecular linked with bule line in Figure 7C.
CD147 has been shown to be involved in the regulation of tumor cell invasion, metastasis, angiogenesis, energy metabolism and anti-apoptosis. Firstly, by combining interacting with integrin alpha6beta1, CD147 take part in FAK P13K-Ca (2+) and MARK signal pathway, interstitial collagenase (MMP-1) is produced and CD147-MMP-1 complex is formed at the tumor cell surface, thus modifying the tumor cell pericellular matrix to promote invasion [37–39]. Secondly, CD147 is a receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN combination, increasring the potential metastasis [40]. Thirdly, it can influence the VEGF/VEGF receptor system of endothelial cells and increase the blood supply for tumor [41]. For glycolytic energy metabolism, CD147 promote the lactate transportion to feed the tumor with the help of AMPK and MCT1/2 [42, 43]. Last but not least, CD147 can down-regulate Beclin 1 and inhibit starvation-induced autophagy through the PI3K/Akt/mTOR pathway, modulating the apoptosis of tumor [44, 45]. And our results demonstrated that poor clinical performance for renal cancer patients, such as lymph metastasis, higher TMN and histopathologic stage, bigger tumor size, is usually accompanied by positive CD147. So the survival time for them would be much shorter than CD147 negative patients.

Efforts were made to conduct a comprehensive analysis, but some limitations need to be acknowledged. First, although we have tried but no unpublished data was found, so all included studies were published data. Publication bias existed in 10-year survival and the tumor size. But trim and fill analysis (S3 Appendix) showed the same results which means the result is reliable. Second, survival analysis was not performed by multivariate analyses in most reported studies, this could bring some bias. Third, external virtuality was limited as most included patients were Chinese. Last, the definition of CD147 positive expressin criteria in all studies isn’t unified, which could bring some potential bias, fortunately, the sensitivity analyses showed a stable result.

To our knowledge, this meta-analysis is the first study which systematically estimates the association between CD147 expression and the survival analysis and its clinicopathological parameters. Nowadays, early diagnosis and early treatment are the fundamental approaches to improve prognosis [46]. Our results found that CD147 positive expression was significant associated with renal cancer tissues, which supported that CD147 could be applied as a potential clinical marker for the early diagnosis of renal cancer. In our study, we demonstrated that CD147 positive expression strongly predicted poorer TNM stage, histopathologic stage, lymph node metastasis and worse survival in the patients with renal cancer. Further studies using additional putative renal cancer surface markers in combination with CD147 are required to evaluate their potential use in predicting patients’ outcome.

**Figure 8: IPA core signaling molecular interaciton with CD147.** (A) interaction between CD147 and MAPK. (B) interaction between CD147 and AKT. (C) interaction between CD147 and ERK. (D) interaction between CD147 and VEGF.
MATERIALS AND METHODS

Search strategy

We searched PubMed (1966-2016), EMBASE (1980-2016), the Cochrane Library (1996-2016), Web of Science (1945-2016), China National Knowledge Infrastructure (1982-2016), and the WanFang databases (1988-2016). The studies were restricted to humans, but not restricted by date, language, or publication status. The following combined search term was used: (kidney neoplasms, renal neoplasms, kidney tumor, renal tumor, kidney cancer, renal cancer, kidney carcinoma, renal carcinoma, clear cell carcinoma) AND (CD147, extracellular matrix metalloproteinase inducer, EMMPRIN, BSG). We combined the term appropriately with MeSH Terms and used an appropriate adjustment for different databases. Details of the search strategies can be found in S1 Appendix.

Criteria for including studies

1. Published or unpublished case control study or cohort study in English or Chinese with the full text available;
2. Cases have survival data or clinical pathological characteristic data, without radiotherapy or chemotherapy or biological therapy before sampling;
3. Pathological methods for confirming renal cancer.
4. CD147 expression based on primary renal cancer tissue, rather than serum or any other kinds of indirect specimen were included.
5. Choosing best quality study for duplication.

Criteria for excluding studies

1. Cell or animal studies, case reports, letters, reviews.
2. The standard of pathological diagnosis was not clear;

Statistical analysis

Bibliographies were scanned by two authors independently to exclude unrelated studies. Then, full text were reviewed, data were extracted independently and controversy were solved by discussion. The software Revman 5.3 and Stata 14.0 were applied to analyze the data. Results were showed with odds ratios (OR) or standard mean difference (SMD) and 95% confidence intervals (95% CI). Fixed-effects model was adopted for non-heterogeneity data (P > 0.1 and I^2 < 50%); otherwise, random-effects model. If possible, heterogeneity subgroup analyses were performed. All P values were 2-sided, and P < 0.05 was considered significant. Sensitive analysis was also performed to evaluate the influences of individual studies on the final effect. Egger’s test was used to assess publication bias (P < 0.05 was considered statistically significant). If publication bias was confirmed, a trim-and-fill method developed by Duval and Tweedie was implemented to adjust for this bias [21]. Then, we replicated the funnel plot with their “missing” counterparts around the adjusted summary estimate.

Bioinformatics analysis

Firstly, we used GOpubmed (http://www.gopubmed.com/web/gopubmed/) with the Search term “Antigens, CD147”[mesh]” to get information about the current related published studies with a global perspective. Secondly, we applied String version10 (http://string-db.org/) to explore the interaction between CD147 and other molecules. We chose the organism with Homo sapiens, and matched the information with different minimum required interaction score, active interaction sources and max number of interactors. Thirdly, IPA (Ingenuity PathwayAnalysis) (http://www.ingenuity.com/) was employed to uncover the interaction network between CD147 and other molecules with different threshold without species restriction. And IPA pathway explorer was used to explore some important signaling pathways which CD147 has take parted in.

Abbreviations

CNKI: Chinese periodical full text database
CBM: China Biology Medicine disc
RCC: Renal cell carcinoma
EMMPRIN: extracellular matrix metalloproteinase inducer
OR: odds ratios
MCT: monocarboxylate transporter
HR: hazard ratio
CI: confidence intervals
OS: overall survival
IPA: Ingenuity PathwayAnalysis
GPVI: Glycoprotein VI
VEGF: vascular endothelial growth factor
BSG: Basigin
SMD: standard mean difference

Author contributions

Hui Li conceived the study and drafted the paper. Dongwen Wu participated in drafting the paper and carried out the Statistical analysis. Shupeng Shi, Yadong Xu and Lin Wei searched the lectures. Jing Liu and Yanting Liu did data extraction and quality assessment.

CONFLICTS OF INTEREST

The authors declare that they have no conflict of interests.
FUNDING

No Funding.

REFERENCES

1. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization classification of tumours. Pathology and genetics of tumors of the urinary system and male genital organs. Lyon: IARC Press; 2004. pp. 10-34.

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66:7–30.

3. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER stat fact sheets: kidney and renal pelvis cancer [Internet]. 2016. http://seer.cancer.gov/statfacts/html/kidrp.html.

4. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015; 67:913–24.

5. Chin AI, Lam JS, Figlin RA, Belldegrun AS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol. 2006; 8:1–7.

6. Kim Y, Choi JW, Lee JH, Kim YS. Expression of lactate/ H+ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses. Hum Pathol. 2015; 46:104–12.

7. Ping JG, Wang F, Pu JX, Hou PF, Chen YS, Bai J, Zheng JN. The expression of Cullin1 is increased in renal cell carcinoma and promotes cancer cell proliferation, migration, and invasion. Tumour Biol. 2016; 37:12823–31.

8. Xiaon C, Liu H, Chen Z, Yu Y, Liang C. Prognostic role of survivin in renal cell carcinoma: A system review and meta-analysis. Eur J Intern Med. 2016; 33:102–07.

9. Chen Y, Gou X, Kong DK, Wang X, Wang J, Chen Z, Huang C, Zhou J. EMMPRIN regulates tumor growth and metastasis by recruiting bone marrow-derived cells through paracrine signaling of SDF-1 and VEGF. Oncotarget. 2015; 6:32575–85. doi: 10.18632/oncotarget.5331.

10. Caudroy S, Polette M, Tournier JM, Burlet H, Toole B, Zucker S, Birembaut P. Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J Histochem Cytochem. 1999; 47:1575–80.

11. Zeng HZ, Qu YQ, Liang AB, Deng AM, Zhang WJ, Xiu B, Wang H, Wang H. Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance. Neoplasma. 2011; 58:449–54.

12. Yu YH, Morales J, Lee JJ, El-Naggar AK, Vigneswaran N. CD147 and Ki-67 overexpression confers poor prognosis in squamous cell carcinoma of oral tongue: a tissue microarray study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 119:553–65.

13. Ishibashi Y, Matsumoto T, Niwa M, Suzuki Y, Omura N, Hanyu N, Nakada K, Yanaga K, Yamada K, Ohkawa K, Kawakami M, Urashima M. CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer. 2004; 101:1994–2000.

14. Hou X, Chen H, Jin F, Wu W, Li Y, Long J, Song X, Luo M, Bi T, Li Z, He Q. Expressions of CD147, MMP-2 and MMP-9 in laryngeal carcinoma and its correlation with poor prognosis. Pathol Oncol Res. 2014; 20:475–81.

15. Luo HR, et al. Expression of CD147 and surviving in renal cell carcinoma and their correlation with clinicopathologic parameters. Journal of Wenzhou Medical University. 2016; 56-60.

16. Rabien A, Stephan C, Kilić E, Weichert W, Kristiansen G, Miller K, Jung K, Erbersdobler A. Renal cell neoplasias: reverse-induction of cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis. J Transl Med. 2013; 11:258.

17. KE M, et al. Expression of CD147, E-cadherin and their significances of CD147, matrix metalloproteinase-9 and survivin in renal cell carcinoma: tissue microarrays. CHINA MODERN DOCTOR; 2013. pp. 63–5.

18. Tsai WC, Sheu LF, Nieh S, Yu CP, Sun GH, Lin YF, Chen A, Jia JS. Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters. World J Urol. 2007; 25:73–80.

19. Kim Y, Choi JW, Lee JH, Kim YS. Expression of lactate/ H+ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses. Hum Pathol. 2015; 46:104–12.

20. Wang S, Wang H, Qin W, Sun H, Gu R. [The expressions and their significances of CD147, matrix metalloproteinase-9 and vascular endothelial growth factor in renal cell carcinoma]. [Article in Chinese]. Journal of Bengbu Medical College. 2011; 11: 1194-1197,1200.

21. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56:455–63.

22. Liang YX, He HC, Han ZD, Bi XC, Dai QS, Ye YK, Qin WJ, Zeng GH, Zhu G, Xu CL, Zhong WD. CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value. Cancer Invest. 2009; 27:788–93.

23. Jin JS, Hsieh DS, Lin YF, Wang JY, Sheu LF, Lee WH. Increasing expression of extracellular matrix metalloproteinase inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Urol. 2006; 13:573–80.
24. Liu Z. EMMPRIN. MMP-2 Expression and Relationship to Invasion and Metastasis in Human Renal Clear Cell Carcinoma. Fujian Medical university. 2007; p. 44.
25. Ma Y. The expressions and their significances of EMMPRIN and Fascin in renal cell carcinoma. Qingdao University. 2009; p. 43.
26. Chen YB. The expressions and its clinical significances of EMMPRIN in human renal clear cell carcinoma. Huazhong University of Science and Technology. 2010; p. 42.
27. Suzuki S, Sato M, Senoo H, Ishikawa K. Direct cell-cell interaction enhances pro-MMP-2 production and activation in co-culture of laryngeal cancer cells and fibroblasts: involvement of EMMPRIN and MT1-MMP. Exp Cell Res. 2004; 293:259–66.
28. Fisel P, Stühler V, Winter S, Rausch S, Hennenlotter J, Nies AT, Stenzl A, Scharpf M, Fend F, Kruck S, Bedke J, Schwab M, Schaeffeler E. CD147, the ancillary protein of MCT4, as marker for prognosis and clinical outcome in primary clear cell renal cell carcinoma and metastasis. Clin Ther. 2015; 37:e75–76.
29. Wang SC. The expressions and their significances of CD147, matrix metalloproteinase-9 and vascular endothelial growth factor in renal cell carcinoma. The Fourth Military Medical University; 2009. p. 41.
30. Tang J, Wu YM, Zhao P, Yang XM, Jiang JL, Chen ZN. Overexpression of HAb18G/CD147 promotes invasion and metastasis via alpha3beta1 integrin mediated FAK-paxillin and FAK-Pi3K-Ca2+ pathways. Cell Mol Life Sci. 2008; 65:2933–42.
31. Lim M, Martinez T, Jablons D, Cameron R, Guo H, Toole B, Li JD, Basbaum C. Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett. 1998; 441:88–92.
32. Guo H, Li R, Zucker S, Toole BP. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res. 2000; 60:888–91.
33. Seizer P, Borst O, Langer HF, Bültmann A, Münch G, Herouy Y, Stellos K, Krämer B, Bigalke B, Büchele B, Bachem MG, Vestweber D, Simmet T, et al. EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction. Thromb Haemost. 2009; 101:682–86.
34. Bougatéf F, Quemener C, Kellouche S, Naimi B, Podgorniak MP, Millot G, Gabison EE, Calvo F, Dosquet C, Lebbé C, Menashi S, Mourah S. EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2α-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood. 2009; 114:5547–56.
35. Su J, Chen X, Kanekura T. A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis. Cancer Lett. 2009; 273:140–47.
36. Maekawa F, Minehira K, Kadomatsu K, Pellerin L. Basal and stimulated lactate fluxes in primary cultures of astrocytes are differentially controlled by distinct proteins. J Neurochem. 2008; 107:789–98.
37. Gou X, Ru Q, Zhang H, Chen Y, Li L, Yang H, Xing J, Chen Z. HAb18G/CD147 inhibits starvation-induced autophagy in human hepatoma cell SMMC7721 with an involvement of Beclin 1 down-regulation. Cancer Sci. 2009; 100:837–43.
38. Fang F, Wang L, Zhang S, Fang Q, Hao F, Sun Y, Zhao L, Chen S, Liao H, Wang L. CD147 modulates autophagy through the PI3K/Akt/mTOR pathway in human prostate cancer PC-3 cells. Oncol Lett. 2015; 9:1439–45.
39. Huang L, Xu A, Li T, Han W, Wu S, Wang Y. Detection of perioperative cancer antigen 72-4 in gastric juice pre- and post-distal gastrectomy and its significances. Med Oncol. 2013; 30:651.